In the study, BioLineRx expects to investigate the safety, phamacokinetics and tolerability of BL-1021 in healthy volunteers.
The primary endpoints of the study are to assess the safety and tolerability of a single administration or multiple administrations of BL-1021.
However, the secondary endpoints are the pharmacokinetics of single or multiple doses of BL-1021 in healthy subjects.
BioLineRx CEO Kinneret Savitsky said based on the promising results from their pre-clinical studies, they believe it has the potential to provide improved efficacy without the side effects associated with many existing medications.